Dr. Chen Gang, MD, PhD
Position:
· Chief Physician
· Professor
· Doctoral Supervisor
· Director of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Wenzhou Medical University
· Director of the Education Department, The First Affiliated Hospital of Wenzhou Medical University
· Assistant Dean of Alberta Institute, Wenzhou Medical University
· Head of First-Class Construction Discipline (A Category) of Surgery, Zhejiang Province
· Director of Abdominal Surgery Collaborative Innovation Center, Wenzhou City
Institution:
· The First Affiliated Hospital of Wenzhou Medical University
Education:
· 1997 - 2002: Bachelor's Degree in Clinical Medicine, Medical School, Wuhan University of Science and Technology
· 2002 - 2008: Doctoral Degree in Surgery, Tongji Medical College, Huazhong University of Science and Technology
· 2012 - 2014: Postdoctoral Research, Mayo Clinic, USA
Research Interests:
· Impact of Tumor Microenvironment on Malignant Progression of Liver Cancer and Molecular Mechanisms
· Molecular Model Construction and Clinical Application Research for Early Diagnosis and Prognosis of Cholangiocarcinoma
· Exploration of Personalized Treatment for Mid-to-Late Stage Hepato-Cholangiocarcinoma
· Molecular Mechanisms of Organ Injury in Severe Acute Pancreatitis
Work Experience:
· 2008 - 2009: Resident Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2009 - 2010: Lecturer and Attending Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2010 - 2012: Associate Professor and Attending Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2012 - 2017: Associate Professor and Associate Chief Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2018: Professor and Associate Chief Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2014 - 2020: Deputy Director of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2019 - Present: Professor and Chief Physician, Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University
· 2020 - Present: Director of the Education Department, The First Affiliated Hospital of Wenzhou Medical University
· 2020 - Present: Assistant Dean, Alberta Institute, Wenzhou Medical University
Awards and Honors:
· Third Tier Talent of Wenzhou City's 551 Talent Project (2011)
· Third Tier Talent of Zhejiang Province's 151 Talent Project (2013)
· Young Backbone Teacher of Wenzhou Medical University (2013)
· Zhejiang Province Medical New Star (2017)
· Young Top Talent of Zhejiang Province’s Ten Thousand Talent Program (2018)
· Leading Talent of Zhejiang Province's Universities (2020)
Academic Positions:
· Member, Hepatobiliary Tumor Group, American Association for the Study of Liver Diseases (AASLD) (2015 - Present)
· Member, Tumor Microenvironment Group, American Association for Cancer Research (AACR) (2016 - Present)
· Member, Artificial Intelligence Tumor Diagnosis and Treatment Committee, Zhejiang Anti-Cancer Association (2017 - Present)
· Member, Tumor Data Intelligent Physics Therapy Committee, Zhejiang Mathematical Medical Society (2018 - Present)
· Standing Committee Member, Medical Education Branch, Zhejiang Medical Association (2020 - Present)
Project Review:
· National Natural Science Foundation of China (2020 - Present)
· Zhejiang Provincial Natural Science Foundation (2017 - Present)
· Wenzhou Science and Technology Bureau Science and Technology Projects (2012 - Present)
Editorial Board:
· Special Editor, Hepatobiliary and Pancreatic Surgery Journal (2015 - Present)
· Editorial Board Member, World Journal of Clinical Oncology (2018 - Present)
Journal Reviewer:
· Asia-Pacific Journal of Clinical Oncology
· Cancer Letter
· Cell Proliferation
· Cell Death and Differentiation
· Cell Death and Diseases
· EBioMedicine
· European Journal of Gastroenterology and Hepatology
· Gene
· Hepatology
· Journal of Cancer
· Journal of Experimental & Clinical Cancer Research
· Life Science
· Oncotarget
· Signal Transduction and Targeted Therapy
· Theranostics
Research Projects:
1. Role and Mechanism of DPP4/NRF2/FSP1-Mediated Non-Classical Ferroptosis Pathway in Sorafenib Resistance in Liver Cancer (2020, National Natural Science Foundation of China, 550,000 RMB)
2. Mechanism of Periostin/CCL2/CD36 Signaling Axis in Promoting Formation of Metastasis-Initiating Cells in Liver Cancer (2017, National Natural Science Foundation of China, 580,000 RMB)
3. Development and Application of New Precision Medical Technologies for Liver Cancer (2017, Major Project of National Health Commission, 500,000 RMB)
4. Molecular Mechanism of Liver Cancer Cells Gaining Stem-Like Phenotype through Periostin Gene Autocrine Expression (2016, Zhejiang Provincial Natural Science Foundation, 90,000 RMB)
5. Cytoprotective Mechanism of Lipoxin A4 Activating Nrf2 Pathway to Improve Severe Acute Pancreatitis-Related Lung Injury (2015, National Natural Science Foundation of China, 510,000 RMB)
6. Molecular Mechanism of EphA1/EphrinA1 Pathway Regulating EPCs Homing to Liver Cancer Neovascularization (2012, National Natural Science Foundation of China, 230,000 RMB)
7. Application of Controllable EphA1 Gene Expression Endothelial Progenitor Cells in Anti-Angiogenesis Treatment of Liver Cancer (2011, New Teacher Fund for Doctoral Program of Ministry of Education, 40,000 RMB)
8. Preliminary Study on Targeted Angiogenesis Therapy of Liver Cancer Using Controllable Endothelial Progenitor Cells as Carriers and Targets (2010, Zhejiang Provincial Natural Science Foundation, 100,000 RMB)
Publications:
1. Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med, 2021 Jun 4. Online ahead of print.
2. Deng T, Ye Q, Jin C, Wu M, Chen K, Yang J, Chen Z, Yu X, Chen G, Wang Y. Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma. Aging (Albany NY), 2021 Mar 3;13(5):7481-7498.
3. Wang Y, Yu H, Xie X, Deng T, Ye L, Wu L, Ding X, Yang Z, Zhu Q, Li J, Zheng Y, Yu Z, Chen G. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway. Oncogene, 2021 Jun 2. Online ahead of print.
4. Chen S, Zhu J, Sun LQ, Liu S, Zhang T, Jin Y, Huang C, Li D, Yao H, Huang J, Qin Y, Zhou M, Chen G, Zhang Q, Ma F. LincRNA-EPS alleviates severe acute pancreatitis by suppressing HMGB1-triggered inflammation in pancreatic macrophages. Immunology, 2021 Jan 29. doi: 10.1111/imm.13313.
5. Xie X, Wang Y, Zhang S, Li J, Yu Z, Ding X, Ye L, Gong P, Zhu Q, Li J, Chen Z, Yao X, Du Z, Zeng Q, Chen H, Yang Z, Chen G. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma. Aging (Albany NY), 2021 Jan 20;13(2):2959-2981.
6. Shi Z, Wang Y, Ye W, Lin Z, Deng T, Zhang T, Zhao J, Tong Y, Shan Y, Chen G. The LipoxinA4 receptor agonist BML-111 ameliorates intestinal disruption following acute pancreatitis through the Nrf2-regulated antioxidant pathway. Free Radic Biol Med, 2021 Feb 1;163:379-391.
7. Deng L, Deng T, Luo D, Deng Z, Peng C, Chen G, Xiong G. A new modified canine model of portal vein thrombosis. Acta Biochim Biophys Sin (Shanghai), 2020 Dec 31:gmaa165. (Co-corresponding)
8. Deng L, Deng Z, Chen K, Chen Z, Chen G, Xiong G. Endovascular Repair of Persistent Sciatic Artery With Limb Ischemia: A Wrong Choice? Front Surg, 2020 Nov 16;7:582753. (Co-corresponding)
9. Deng L, Wang Y, Zhao J, Tong Y, Zhang S, Jin C, Chen K, Bao W, Yu Z, Chen G. The prognostic value of sarcopenia combined with hepatolithiasis in
Reviews and Commentary
1. Wang M, Chen Z, Guo P, Wang Y, Chen G. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. J Cell Mol Med. 2020 Dec 4;25(2):618-28.
2. Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: A new vision for cholangiocarcinoma. J Cell Mol Med. 2019, 23(1):59-69.
3. Wu LJ, Chen ZY, Wang Y, Zhao JG, Xie XZ, Chen G. Organoids of liver diseases: From bench to bedside. World J Gastroenterol. 2019, 25(16):1913-1927.
4. Pengyi Guo, Haitao Yu, Yi Wang, Xiaozai Xie, Gang Chen. Exosome: An Emerging Participant in the Development of Liver Disease. Hepatitis Monthly 2017.
5. Xiaozai Xie, Pengyi Guo, Haitao Yu, Yi Wang, Gang Chen. Ribosomal proteins: Insight into molecular roles and functions in hepatocellular carcinoma. Oncogene, 2018, 37(3):277-285.
6. Haitao Yu, Pengyi Guo, Xiaozai Xie, Yi Wang, Gang Chen. Ferroptosis, a new form of cell death, and its relationships with tumorous diseases. J Cell Mol Med 2017, 21:648-657.
International Conference Presentations
1. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.
15th World Congress on Advances in Oncology and 13th International Symposium on Molecular Medicine, 2010, Athens, Greece.
2. Sulfatase2 promotes angiogenesis of hepatocellular carcinoma partly through activating TGFβ1/periostin signaling pathway.
Digestive Disease Week (DDW), 2014, Chicago, USA.
Conference Abstracts
1. Yu HT, Guo PY, Xie XZ, Wang Y, Chen G. PLVAP as a new therapeutic target for treatment of cholangiocarcinoma. May 2017, DDW, Chicago.
2. Guo PY, Yu HT, Xie XZ, Wang Y, Chen G. Exosomes derived from CD133+ hepatocellular carcinoma (HCC) cells can promote transformation of stem cell-like properties via the Akt/GSK3β/Snail and Cyclin D1 pathway. April 2017, AACR Meeting, Washington DC.
3. Xiaozai Xie, Sina Zhang, Yi Wang, Zhengping Yu, Longyu Ye, Qiandong Zhu, Junjian Li, Ziyan Chen, Zeng Qiqiang, Gang Chen. A novel lncRNA panel improves the prediction of survival in high-risk cholangiocarcinoma. November 2019, AASLD Meeting, Boston.
4. Yi Wang, Gang Chen. Association of TNFRSF12A Methylation Site Prognosis in Hepatocellular Carcinoma with a History of Alcohol Consumption.
November 2019, AASLD Meeting, Boston.
Patents
1. A diagnostic kit for early detection of liver cancer based on the POSTN gene; First author; Patent Number: 201710070376.3
2. A rapid expansion system for endothelial progenitor cells; First author; Patent Number: 201610017696.8
3. PTCD puncture channel sealing device and method; First author; Invention and Utility Model Patents Authorized; Patent Number: 202010940673.0
4. Adjustable pressure hepatic portal occluder and method; First author; Utility Model Patent Authorized; Patent Number: 202011002928.5
5. Non-invasive biomarkers for cholangiocarcinoma based on gut microbiota relative abundance, screening methods, and applications; First author; Patent Number: 202011341383.0
Books
1. Palliative Treatment of Malignant Tumors, Henan Science and Technology Press, 2015, Co-author.
